北京大学第三医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 肝细胞癌Hepatocellular carcinoma11 篇牵头论文牵头 1 项开放试验
- 胃癌Stomach cancer24 篇牵头论文牵头 2 项开放试验
- 脊索瘤Chordoma6 篇牵头论文
- 骨肉瘤Osteosarcoma7 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
- 神经母细胞瘤Neuroblastoma0 篇牵头论文
- 尤文肉瘤Ewing sarcoma0 篇牵头论文
- 多发性骨髓瘤Multiple myeloma5 篇牵头论文
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia0 篇牵头论文
- β 地中海贫血Beta thalassaemia0 篇牵头论文
- 血友病 AHaemophilia A1 篇牵头论文
- 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura0 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder2 篇牵头论文
- IgG4相关性疾病IgG4-related disease2 篇牵头论文
- 烟雾病Moyamoya disease2 篇牵头论文
- 大动脉炎Takayasu arteritis1 篇牵头论文
- 肝包虫病Hepatic echinococcosis0 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis52 篇牵头论文牵头 2 项开放试验
- 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文牵头 1 项开放试验
- 法布雷病Fabry disease1 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
- 白塞病Behçet disease0 篇牵头论文
- IgA 肾病IgA nephropathy1 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
- 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文
未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、肝母细胞瘤、视网膜母细胞瘤、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、非典型溶血性尿毒症综合征、范可尼贫血、重症肌无力、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、肺淋巴管平滑肌瘤病、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.07%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 17 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- 分期
- 不分期
- 开始
- 2026-08
- 登记号
- NCT07760012
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学第三医院北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文11
- Expression and prognostic significance of MLH1 and GPRC5C in resectable hepatocellular carcinoma.
- Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation.
- Stereotactic radiotherapy with Gamma Master System® for palliation of hepatocellular carcinoma in patients with liver cirrhosis.
- SPINK1 Overexpression Correlates with Hepatocellular Carcinoma Treatment Resistance Revealed by Single Cell RNA-Sequencing and Spatial Transcriptomics.
- Prognostic Value of N1/N2 Neutrophils Heterogeneity and Tertiary Lymphoid Structure in Hepatocellular Carcinoma Patients.
- CMTM7 shapes the chronic inflammatory and immunosuppressive tumor microenvironment in hepatocellular carcinoma as an M2 macrophage biomarker.
- Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma.
- Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma.
- Allosteric regulation of the lid domain of PCK2 as a novel strategy for modulating mitochondrial dynamics.
- Advances in radiotherapy and immunity in hepatocellular carcinoma.
- Peroxisome-related genes in hepatocellular carcinoma correlated with tumor metabolism and overall survival.
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 24 篇,占 0.2%。
北京有 15 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
- 分期
- II期
- 开始
- 2023-04
- 登记号
- NCT06792162
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学第三医院北京
- 即将招募Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer
- 分期
- 不分期
- 开始
- 2019-03
- 登记号
- NCT03857737
年龄未注明(登记的条件)
牵头:北京大学第三医院北京
- 正在招募Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- 分期
- 不分期
- 开始
- 2026-06
- 登记号
- NCT07552402
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南宁、成都、杭州、武汉、石家庄、福州、苏州、银川
- 正在招募Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- 分期
- III期
- 开始
- 2025-02
- 登记号
- NCT06731478
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文24
- Helicobacter pylori infection status and evolution of gastric cancer.
- Dynamic changes of host immune response during Helicobacter pylori-induced gastric cancer development.
- Luteolin improves precancerous conditions of the gastric mucosa by binding STAT3 and inhibiting LCN2 expression.
- Ultrasound-triggered topical oxygen delivery enhances synergistic sonodynamic and antibody therapies against hypoxic gastric cancer.
- Cmtm4 Deficiency Inhibits Helicobacter pylori-Induced Gastric Carcinogenesis.
- Raman spectroscopy and machine learning for early detection of gastric cancer and Helicobacter pylori with gastric juice.
- YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis.
- Helicobacter pylori with trx1 high expression promotes gastric diseases via upregulating the IL23A/NF-κB/IL8 pathway.
- Machine learning models to predict submucosal invasion in early gastric cancer based on endoscopy features and standardized color metrics.
- Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
- Long-term outcomes of additional surgery versus non-gastrectomy treatment for early gastric cancer after non-curative endoscopic submucosal dissection: a meta-analysis.
- The expression and function of the B7 family in Helicobacter pylori infection and gastric carcinogenesis process.
- Antitumor effect of luteolin proven by patient-derived organoids of gastric cancer.
- Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer.
- Double contrast-enhanced ultrasound for the preoperative gross classification of gastric cancer: a comparison with multidetector computed tomography.
- Epigenetic modification facilitates proline synthase PYCR1 aberrant expression in gastric cancer.
- Traditional Chinese medicine for precancerous lesions of gastric cancer: A review.
- Long-Term Outcome of Gastric Mild-Moderate Dysplasia: A Real-World Clinical Experience.
- Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients.
- Effect of Helicobacter pylori on immunotherapy is gaining more attention.
- Influence of Helicobacter pylori infection on PD-1/PD-L1 blockade therapy needs more attention.
- Microbiome changes in the gastric mucosa and gastric juice in different histological stages of Helicobacter pylori-negative gastric cancers.
- Downregulation of FABP5 Suppresses the Proliferation and Induces the Apoptosis of Gastric Cancer Cells Through the Hippo Signaling Pathway.
- Endoscopic grading of gastric atrophy on risk assessment of gastric neoplasia: A systematic review and meta-analysis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
- PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
- Endoscopic Submucosal Dissection Versus Surgery in the Treatment of Early Gastric Cancer
- Evaluation of the Preventive Effect of Chlorhexidine Acetate Gargle for Upper Gastrointestinal Tract Infection After ESD
- Predictive Factors for Roux Stasis Syndrome
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 5.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 11 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
这些数字背后的记录
牵头的论文6
- Cracking Chordoma's Conundrum: Immune Checkpoints Provide a Potential Modality.
- SMARCB1 orchestrates cellular plasticity and oncogenic pathways in typical and chondroid chordomas.
- Misdiagnosis of primary dumbbell chordoma of the cervical spine.
- Complications and local recurrence of chondrosarcoma and chordoma treated by total tumor resection in thoracic and lumbar spine.
- Hypoxia-Inducible Factor-1α (HIF-1α) as a Factor to Predict the Prognosis of Spinal Chordoma.
- Preliminary study of monoexponential, biexponential, and stretched-exponential models of diffusion-weighted MRI and diffusion kurtosis imaging on differential diagnosis of spinal metastases and chordoma.
早期论文(2016–2020 年)9
- Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma.
- Set-up error and dosimetric analysis of HexaPOD evo RT 6D couch combined with cone beam CT image-guided intensity-modulated radiotherapy for primary malignant tumor of the cervical spine.
- Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target.
- [Anesthesia management of cervical chordoma resection: A case report].
- Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.
- A brief review of chordomas: pathogenesis, prognostic factors and therapeutic targets.
- Radiofrequency ablation in gross total excision of cervical chordoma: ideas and technique.
- Prognostic Factors in Surgical Patients with Chordomas of the Cervical Spine: A Study of 52 Cases from a Single Institution.
- Morphological and dynamic contrast enhanced MR imaging features for the differentiation of chordoma and giant cell tumors in the Axial Skeleton.
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 48 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文7
- Arnicolide D Inhibits Proliferation and Induces Apoptosis of Osteosarcoma Cells through PI3K/Akt/mTOR Pathway.
- Metabolic Landscape of Osteosarcoma: Reprogramming of Lactic Acid Metabolism and Metabolic Communication.
- Transcriptome and single-cell analysis reveal disulfidptosis-related modification patterns of tumor microenvironment and prognosis in osteosarcoma.
- The Dilemma of Balance between Benefits and Losses for Chondromyxoid Fibroma-like Osteosarcoma in Thoracic Spine with Azygos Tumor Thrombosis: A Case Report.
- Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway.
- D-arginine-loaded metal-organic frameworks nanoparticles sensitize osteosarcoma to radiotherapy.
- VPS34 regulates dynamin to determine the endocytosis of mitochondria-targeted zinc oxide nanoparticles in human osteosarcoma cells.
中文论文(未计入)1
早期论文(2016–2020 年)9
- HIF-1α-Mediated Mitophagy Determines ZnO Nanoparticle-Induced Human Osteosarcoma Cell Death both In Vitro and In Vivo.
- Set-up error and dosimetric analysis of HexaPOD evo RT 6D couch combined with cone beam CT image-guided intensity-modulated radiotherapy for primary malignant tumor of the cervical spine.
- Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1.
- Cross Talk Between Autophagy and Apoptosis Contributes to ZnO Nanoparticle-Induced Human Osteosarcoma Cell Death.
- Oleandrin synergizes with cisplatin in human osteosarcoma cells by enhancing cell apoptosis through activation of the p38 MAPK signaling pathway.
- Renal Ewing's sarcoma/primitive neuroectodermal tumor: a case report and literature review.
- Recurrence Factors in Giant Cell Tumors of the Spine.
- Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing.
- Reconstruction of the Upper Cervical Spine Using a Personalized 3D-Printed Vertebral Body in an Adolescent With Ewing Sarcoma.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 23 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
这些数字背后的记录
牵头的论文2
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 24 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 17 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
这些数字背后的记录
中文论文(未计入)1
早期论文(2016–2020 年)3
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 15 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 10
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- 分期
- I期
- 开始
- 2026-05
- 登记号
- NCT07477587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛
- 正在招募Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2023-02
- 登记号
- NCT05565807
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、杭州
- 正在招募Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- 分期
- IV期
- 开始
- 2023-10
- 登记号
- NCT06057402
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、广州、杭州、济南
- 正在招募A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- 分期
- IV期
- 开始
- 2022-03
- 登记号
- NCT05201781
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南京、广州、成都、杭州、福州、西安
- 正在招募Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- 分期
- II期
- 开始
- 2022-04
- 登记号
- NCT05294055
年龄 18 岁 至 65 岁(登记的条件)
牵头:中国医学科学院血液病医院(血液学研究所);另有 6 家列出的医院为研究中心北京、合肥、天津、济南、郑州
- 正在招募A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2022-08
- 登记号
- NCT05299424
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
- 正在招募A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- 分期
- III期
- 开始
- 2022-11
- 登记号
- NCT05623020
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、天津、广州、杭州、武汉、温州、福州、苏州、长春
- 正在招募A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- 分期
- II期
- 开始
- 2021-02
- 登记号
- NCT04634552
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、苏州、西安
- 正在招募A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- 分期
- I/II期
- 开始
- 2021-09
- 登记号
- NCT04973605
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛
- 正在招募A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- 分期
- III期
- 开始
- 2021-10
- 登记号
- NCT05020236
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Push Forward Clinical Management of Hematological Toxicity due to Lenalidomide Overexposure: Model-Informed Precision Dosing for Chinese Population With Renal Insufficiency.
- Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003).
- Vertebral MRI-based radiomics model to differentiate multiple myeloma from metastases: influence of features number on logistic regression model performance.
- Prediction of High-Risk Cytogenetic Status in Multiple Myeloma Based on Magnetic Resonance Imaging: Utility of Radiomics and Comparison of Machine Learning Methods.
- A preliminary study using spinal MRI-based radiomics to predict high-risk cytogenetic abnormalities in multiple myeloma.
中文论文(未计入)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)32
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
- A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
- A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
- Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Ninlaro in Real World Clinical Practice in China
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma
- Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
- A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
- A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Ixazomib Rollover Study
- A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
- Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
- Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
- Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年没有牵头B 细胞急性淋巴细胞白血病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 10 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- 分期
- 未注明
- 开始
- 2024-06
- 登记号
- NCT06450067
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、天津、广州、徐州、成都、武汉、济南、郑州
- 正在招募Phase Ib Clinical Study of Keynatinib
- 分期
- I期
- 开始
- 2020-09
- 登记号
- NCT04807881
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京、成都
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
血液疾病
β 地中海贫血
Beta thalassaemia2021–2025 年没有牵头β 地中海贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 10 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。
血液疾病
血友病 A
Haemophilia A2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 15 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。
血液疾病
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025 年没有牵头血栓性血小板减少性紫癜的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 8 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 12 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
IgG4相关性疾病
IgG4-related disease2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 11 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
烟雾病
Moyamoya disease2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 8 家医院列在烟雾病下全国有 47 家医院列在烟雾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 30 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
这些数字背后的记录
其他疾病
肝包虫病
Hepatic echinococcosis2021–2025 年没有牵头肝包虫病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 6 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。
这些数字背后的记录
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 27 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
牵头的论文2
- Patient journey and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis (IPFLife) in China: a sequential exploratory mixed methods research protocol.
- Development of an Artificial Intelligence Model for Analyzing the Relationship between Imaging Features and Glucocorticoid Sensitivity in Idiopathic Interstitial Pneumonia.
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- Current Status of Diagnosis, Treatment and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis
- Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 52 篇,占 6.7%。
北京有 19 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
- 分期
- IV期
- 开始
- 2023-01
- 登记号
- NCT05923905
年龄 18 岁 至 80 岁(登记的条件)
牵头:北京大学第三医院北京
- 正在招募Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
- 分期
- 未注明
- 开始
- 2019-11
- 登记号
- NCT04454892
年龄未注明(登记的条件)
牵头:北京大学第三医院北京
- 正在招募A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
- 分期
- II/III期
- 开始
- 2025-10
- 登记号
- NCT07082192
年龄 18 岁 至 65 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
- 正在招募The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
- 分期
- I期
- 开始
- 2025-09
- 登记号
- NCT07118319
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文52
- A rare genetic variant in APEX1 is associated with familial amyotrophic lateral sclerosis with slow progression.
- Educational adjustments for the Chinese version of the Edinburgh Cognitive and Behavioral Screen (ECAS): establishing normative data.
- The contralateral co-movement test in a Chinese population with amyotrophic lateral sclerosis.
- Low CD3 level is a risk factor for amyotrophic lateral sclerosis: a Mendelian randomization study.
- Unveiling structural damage of the corpus callosum in amyotrophic lateral sclerosis through diffusion tensor imaging and spread direction perspectives.
- Tetramethylpyrazine Nitrone in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
- Exploring epigenetic modifications as potential biomarkers and therapeutic targets in amyotrophic lateral sclerosis.
- Characteristics of Neuromuscular Ultrasound in Patients with Amyotrophic Lateral Sclerosis.
- Real-world evidence of riluzole on survival and ALSFRS change in a Chinese ALS cohort.
- Characteristics and influencing factors of pain in amyotrophic lateral sclerosis: a focus on symptom management.
- Two-step Mendelian randomization reveals a lipid-driven protective effect of type 2 diabetes on ALS.
- Concomitant presence of a novel ARPP21 variant and CNVs in Chinese familial amyotrophic lateral sclerosis-frontotemporal dementia patients.
- Amyotrophic Lateral Sclerosis With Concurrent LHON-associated m.14484T>C Mutation: A Case Report and Literature Review.
- The experience of pain symptoms in patients with amyotrophic lateral sclerosis: a qualitative study.
- Smell loss is associated with cognitive impairment in amyotrophic lateral sclerosis patients.
- Immune-mediated diseases are associated with a higher risk of ALS incidence: a prospective cohort study from the UK Biobank.
- Whole-Genome Sequencing Identified a Novel Mutation in the N-Terminal Domain of KIF5A in Chinese Patients with Familial Amyotrophic Lateral Sclerosis.
- Validation of the Center for Neurologic Study Bulbar Function Scale-Chinese version in a population with amyotrophic lateral sclerosis.
- Lower creatinine-to-cystatin c ratio associated with increased risk of incident amyotrophic lateral sclerosis in the prospective UK biobank cohort.
- The integrity of the corticospinal tract and corpus callosum, and the risk of ALS: univariable and multivariable Mendelian randomization.
- Neutrophils Are Associated with Higher Risk of Incident Amyotrophic Lateral Sclerosis in a BMI- and Age-Dependent Manner.
- Cost analysis of amyotrophic lateral-sclerosis management in China.
- Lipids and amyotrophic lateral sclerosis: A two-sample Mendelian randomization study.
- Mutation-specific metabolic profiles in presymptomatic amyotrophic lateral sclerosis.
- Neutrophils: a subgroup of neglected immune cells in ALS.
- A de novo c.113 T > C: p.L38R mutation of SPTLC1: case report of a girl with sporadic juvenile amyotrophic lateral sclerosis.
- An identical DCTN1 mutation in two Chinese siblings manifest as dHMN and ALS respectively: a case report.
- Human endogenous retrovirus K (HERV-K) env in neuronal extracellular vesicles: a new biomarker of motor neuron disease.
- Assessment of bidirectional relationships between 98 genera of the human gut microbiota and amyotrophic lateral sclerosis: a 2-sample Mendelian randomization study.
- Hypermetabolism associated with worse prognosis of amyotrophic lateral sclerosis.
- Genotype-phenotype correlations in a chinese population with familial amyotrophic lateral sclerosis.
- Dietary-Derived Essential Nutrients and Amyotrophic Lateral Sclerosis: A Two-Sample Mendelian Randomization Study.
- Assessing the role of blood pressure in amyotrophic lateral sclerosis: a Mendelian randomization study.
- Small fiber neuropathy for assessment of disease severity in amyotrophic lateral sclerosis: corneal confocal microscopy findings.
- Association between type 2 diabetes and amyotrophic lateral sclerosis.
- Amyotrophic lateral sclerosis: new era, new challenges.
- Disease duration of progression is helpful in identifying isolated bulbar palsy of amyotrophic lateral sclerosis.
- Induced pluripotent stem cell-derived motor neurons from amyotrophic lateral sclerosis (ALS) patients carrying different superoxide dismutase 1 mutations recapitulate pathological features of ALS.
- Epidemiology and factors predicting survival of amyotrophic lateral sclerosis in a large Chinese cohort.
- Trends in the clinical features of amyotrophic lateral sclerosis: A 14-year Chinese cohort study.
- Chinese validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale.
- Daytime sleepiness might increase the risk of ALS: a 2-sample Mendelian randomization study.
- Validation of the pathogenic role of rare DNAJC7 variants in Chinese patients with amyotrophic lateral sclerosis.
- Physical activity and amyotrophic lateral sclerosis: a Mendelian randomization study.
- GLT8D1 may not be significant in Chinese sporadic amyotrophic lateral sclerosis patients.
- The complement C7 variant rs3792646 is associated with amyotrophic lateral sclerosis in a Han Chinese population.
- TBK1 variants in Chinese patients with amyotrophic lateral sclerosis.
- Leukocyte telomere length and amyotrophic lateral sclerosis: a Mendelian randomization study.
- Prognosis of amyotrophic lateral sclerosis with cognitive and behavioural changes based on a sixty-month longitudinal follow-up.
- Loss of appetite in patients with amyotrophic lateral sclerosis is associated with weight loss and anxiety/depression.
- Myoglobin: a new biomarker for spinal and bulbar muscular atrophy?
- A natural history comparison of SOD1-mutant patients with amyotrophic lateral sclerosis between Chinese and German populations.
中文论文(未计入)7
- [Progress in the application of uric acid-lowering treatments in amyotrophic lateral sclerosis].
- [Cortical thickness and cognitive impairment in patients with amyotrophic lateral sclerosis].
- [Genetic distribution in Chinese patients with hereditary peripheral neuropathy].
- [Cu/Zn superoxide dismutase and amyotrophic lateral sclerosis: a review of the current state of basic research and clinical trials].
- [Corneal confocal microscopy detects small-fiber neuropathy in patients with amyotrophic lateral sclerosis].
- [Rare variants of HSPB1 are probably associated with amyotrophic lateral sclerosis].
- [Association between rare UBQLN2 variants and amyotrophic lateral sclerosis in Chinese population].
早期论文(2016–2020 年)36
- The protective role of pre-morbid type 2 diabetes in patients with amyotrophic lateral sclerosis: a center-based survey in China.
- Twelve-month duration as an appropriate criterion for flail arm syndrome.
- Education, intelligence, and amyotrophic lateral sclerosis: A Mendelian randomization study.
- Reply to "Life Course Adiposity and Amyotrophic Lateral Sclerosis".
- Life Course Adiposity and Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study.
- Multicentre, prospective registry study of amyotrophic lateral sclerosis in mainland China (CHALSR): study protocol.
- Anesthetic management of a parturient with amyotrophic lateral sclerosis undergoing cesarean section.
- Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study.
- Whole-exome sequencing identified novel KIF5A mutations in Chinese patients with amyotrophic lateral sclerosis and Charcot-Marie-Tooth type 2.
- Elevated cerebrospinal fluid homocysteine is associated with blood-brain barrier disruption in amyotrophic lateral sclerosis patients.
- Changes in the concentrations of trimethylamine N-oxide (TMAO) and its precursors in patients with amyotrophic lateral sclerosis.
- [Decremental responses to repetitive nerve stimulation at slow rates in amyotrophic lateral sclerosis].
- Cognitive and behavioral impairments in German and Chinese ALS populations - a post-hoc comparison of national study data.
- Vestibular evoked myogenic potentials and their clinical utility in patients with amyotrophic lateral sclerosis.
- Two rare variants of the ANXA11 gene identified in Chinese patients with amyotrophic lateral sclerosis.
- [Application value of motor unit number index in patients with amyotrophic lateral sclerosis].
- Identification of an A4V SOD1 mutation in a Chinese patient with amyotrophic lateral sclerosis without the A4V founder effect common in North America.
- Amyotrophic lateral sclerosis in Beijing: Epidemiologic features and prognosis from 2010 to 2015.
- The epidemiology and genetics of Amyotrophic lateral sclerosis in China.
- Comparison of optical coherence tomography findings and visual field changes in patients with primary open-angle glaucoma and amyotrophic lateral sclerosis.
- Screening for TUBA4A mutations in a large Chinese cohort of patients with ALS: re-evaluating the pathogenesis of TUBA4A in ALS.
- Using the Capture-Recapture Method to Estimate the Incidence of Amyotrophic Lateral Sclerosis in Beijing, China.
- A novel mutation of BICD2 gene associated with juvenile amyotrophic lateral sclerosis.
- Clinical Features of Isolated Bulbar Palsy of Amyotrophic Lateral Sclerosis in Chinese Population.
- Diets for Patients with Amyotrophic Lateral Sclerosis: Pay Attention to Nutritional Intervention.
- Whole-exome sequencing in amyotrophic lateral sclerosis suggests NEK1 is a risk gene in Chinese.
- CHCHD10 mutations in patients with amyotrophic lateral sclerosis in Mainland China.
- DCTN1 gene analysis in Chinese patients with sporadic amyotrophic lateral sclerosis.
- No Evidence for Pathogenic Role of UBQLN2 Mutations in Sporadic Amyotrophic Lateral Sclerosis in the Mainland Chinese Population.
- Association Between Rectus Abdominis Denervation and Ventilation Dysfunction in Patients with Amyotrophic Lateral Sclerosis.
- Elimination Rate of Serum Lactate is Correlated with Amyotrophic Lateral Sclerosis Progression.
- MATR3 mutation analysis in a Chinese cohort with sporadic amyotrophic lateral sclerosis.
- Two distinct clinical features and cognitive impairment in amyotrophic lateral sclerosis patients with TARDBP gene mutations in the Chinese population.
- The presence of spontaneous EMG activity in sternocleidomastoid is associated with ventilatory dysfunction in ALS.
- The Edinburgh Cognitive and Behavioural ALS Screen in a Chinese Amyotrophic Lateral Sclerosis Population.
- [Association of serum uric acid level with amyotrophic lateral sclerosis].
它在 ClinicalTrials.gov 上的全部试验(任何状态)25
- Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
- Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)
- An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis
- Pleiotropy and Mechanism of Peripheral Nerve Related Genes in the Progression of Amyotrophic Lateral Sclerosis
- Home Care Needs and Current Nursing Status of Patients With Amyotrophic Lateral Sclerosis
- Explore Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China
- Sleep Disorders and the Onset and Progression of ALS
- Low Dose IL-2 in the Treatment of Immune-associated ALS Syndrome
- Appetite and Related Factors in Patients With ALS
- Investigation on Home Care Needs of ALS Patients and Their Caregivers
- Efficacy and Safety of Nitrazine in the Treatment of ALS
- Registration Study of Amyotrophic Lateral Sclerosis (ALS) in Mainland China
- The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules
- Multimodal Brain Imaging Study
- Correlation Between Intestinal Microflora Metabolites and Amyotrophic Lateral Sclerosis
- Application of Motor Unit Estimation Index in Amyotrophic Lateral Sclerosis and Related Diseases
- Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis
- Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis
- Quantitative Analysis of Precise Brain Volume in Amyotrophic Lateral Sclerosis
- A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
- A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
- The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
- A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
- Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis
其他疾病
脊髓性肌萎缩症
Spinal muscular atrophy北京有 8 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Effects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA
- 分期
- 不分期
- 开始
- 2026-10
- 登记号
- NCT07822711
年龄 6 岁 至 12 岁(登记的条件)
牵头:北京大学第三医院北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
早期论文(2016–2020 年)3
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
其他疾病
法布雷病
Fabry disease2021–2025 年中国大陆作者发表的 73 篇法布雷病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 11 家医院列在法布雷病下全国有 85 家医院列在法布雷病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- 分期
- 未注明
- 开始
- 2025-11
- 登记号
- NCT07187440
年龄 7 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 18 家列出的医院为研究中心北京、南京、合肥、哈尔滨、天津、太原、成都、杭州、汕头、深圳、石家庄、福州、苏州、西安
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 11 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
其他疾病
白塞病
Behçet disease2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
北京有 24 家医院列在白塞病下全国有 149 家医院列在白塞病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
- 分期
- III期
- 开始
- 2023-11
- 登记号
- NCT06145893
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 32 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
牵头的论文1
早期论文(2016–2020 年)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 16 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
这些数字背后的记录
其他疾病
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
北京有 7 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。
其他相关研究
联系这家医院
出示给工作人员或司机的院名卡
北京大学第三医院
Peking University Third Hospital
北京
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。